Traws reports final Phase 2a ratutrelvir data, completes TXM tablet bridging studyNov 12Clinical readoutTraws Pharma, Inc.
Vaxcyte names new chief medical and legal officers, moves up OPUS-1 data timingSep 3Clinical readoutVaxcyte, Inc.
Traws Pharma files prospectus supplement for up to $5.58 million at-the-market stock saleJul 10FinancingTraws Pharma, Inc.